- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- Akero Therapeutics Announces Pricing of Public Offering of Common Stock
- Akero Therapeutics Announces Proposed Public Offering of Common Stock
- Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
- Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
- Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
- Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
More ▼
Key statistics
As of last trade, Akero Therapeutics Inc (AKRO:NSQ) traded at 19.72, 75.29% above the 52 week low of 11.25 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.18 |
---|---|
High | 19.97 |
Low | 18.95 |
Bid | 19.73 |
Offer | 19.78 |
Previous close | 18.93 |
Average volume | 754.96k |
---|---|
Shares outstanding | 68.40m |
Free float | 58.25m |
P/E (TTM) | -- |
Market cap | 1.29bn USD |
EPS (TTM) | -2.85 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:01 BST.
More ▼